home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490754.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
3KB
|
42 lines
Document 0754
DOCN M9490754
TI A 12-month study of the effects of oral zidovudine on neurodevelopmental
functioning in a cohort of vertically HIV-infected inner-city children.
DT 9411
AU Nozyce M; Hoberman M; Arpadi S; Wiznia A; Lambert G; Dobroszycki J;
Chang CJ; St Louis Y; Department of Pediatrics, Bronx-Lebanon Hospital
Center, NY; 10457.
SO AIDS. 1994 May;8(5):635-9. Unique Identifier : AIDSLINE MED/94338599
AB OBJECTIVE: To examine the effects of oral zidovudine on the
neurodevelopmental functioning of HIV-infected children. METHODS: Oral
zidovudine was administered to 54 symptomatic children with vertically
transmitted HIV infection (Centers for Disease Control and Prevention
class P2). All children were recruited from an inner-city pediatric
HIV/AIDS outpatient clinic and ranged in age from 2 months to 12 years
and 11 months (mean age, 3 years) at entry. Neurodevelopmental
functioning, height and weight, and lymphocyte subpopulation data were
ascertained for all the children pretherapy, and 6 and 12 months
post-therapy initiation. RESULTS: Analysis of the 6- and 12-month
post-initiation drug data found no significant change in
neurodevelopmental functioning. Height and weight percentiles remained
the same or improved in the majority of children. CD4+ cell counts
declined over the treatment period with CD4+ counts < 500 x 10(6)/l
observed in 15% of the children pre-therapy, and 33% after 1 year.
CONCLUSION: In contrast with previously published data, the present
study observed no improvement in neurodevelopmental functioning in
HIV-infected children treated with oral zidovudine.
DE Blacks Body Height Body Weight Child Child Development
Disorders/ETIOLOGY/*PREVENTION & CONTROL Child, Preschool Cognition
Disorders/ETIOLOGY/PREVENTION & CONTROL Cohort Studies Female
Hispanic Americans Human HIV Infections/CONGENITAL/COMPLICATIONS/*DRUG
THERAPY/ EPIDEMIOLOGY Infant Leukocyte Count Male
Neuropsychological Tests New York City/EPIDEMIOLOGY Poverty
Psychomotor Disorders/ETIOLOGY/PREVENTION & CONTROL Socioeconomic
Factors Treatment Outcome T4 Lymphocytes Urban Population
Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).